PZRXQ OTC
PhaseRx, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
3Y: -0.0%
5Y: -95.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.0001-0.0002
Volume250
Avg Volume233
Beta-2.55
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORobert W. Overell
Employees10
SectorHealthcare
IndustryBiotechnology
IPO Date2016-05-18
Websitephaserx.com
410 West Harrison Street
Seattle, WA 98119
US
Seattle, WA 98119
US
206 805 6300
About PhaseRx, Inc.
PhaseRx, Inc. is a biopharmaceutical company dedicated to developing treatments for inherited enzyme deficiencies affecting the liver. Its therapeutic strategy involves intracellular enzyme replacement, powered by its unique Hybrid mRNA technology platform, which facilitates the production of absent enzymes directly within the body's cells. The company's pipeline includes several programs targeting urea cycle disorders, such as PRX-OTC for ornithine transcarbamylase deficiency, PRX-ASL for argininosuccinate lyase deficiency, and PRX-ASS1 for argininosuccinate synthetase deficiency. Established in 2006, PhaseRx is headquartered in Seattle, Washington.
Latest News
No recent news
Recent Insider Trades
No insider trades found